PharmaLex and Phlexglobal announce merger

25-Jan-2022

Through the merger, the company’s regulatory information management system will be used to support PharmaLex’s overall offering

PharmaLex Group, a provider of specialised services for the pharma, biotech and medtech industries, has announced a merger with Phlexglobal, a technology and services organisation for clinical and regulatory solutions.

Founded in 1997, the company provides its electronic trial master file platform (PhlexTMF) and services to hundreds of global life sciences companies, as well as AI-enabled automation solutions that allow customers to benefit from existing clinical and regulatory training models.

The company’s staff of more than 400 employees, based in the United Kingdom, the United States, India, Poland and Germany, bring their technical skills, along with the company’s market footprint, to PharmaLex. Through the merger, the company’s regulatory information management system will be used to support PharmaLex’s overall offering.

“The merger with PharmaLex provides our clients and the life sciences industry with access to a more robust combined set of capabilities across all of our key value areas,” said John McNeill, CEO of Phlexglobal. “With our shared focus on streamlining the overall development process as well as our cultural values, both Phlexglobal and PharmaLex will deliver greater value to customers.”

Sign up for your free email newsletter

“We are delighted to welcome the Phlexglobal team to the PharmaLex Group, and the opportunity to continue our commitment to innovation by further expanding our technology-enabled service solutions portfolio with the addition of Phlexglobal’s capabilities for eTMF technology and services, as well as their state-of-the-art regulatory operations and automation technologies,” said PharmaLex CEO Dr Thomas Dobmeyer. “The merger enables us to further our goal of becoming a technology-enabled solution provider, and at the same time increasing operational excellence and efficiency through our global subject matter expertise.”

Companies